^
Association details:
| Biomarker: | EGFR L858R + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1359P - Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients
Published date:
10/16/2023
Excerpt:
The MELROSE trial enrolled 150 patients with EGFR-mutated (exon 19 deletion, n=88; L858R mutation, n=62) NSCLC. All patients received osimertinib....The presence of a TP53 mutation was associated with a reduced median PFS (16.4 months) as compared to wild type tumors (27.5 months; p=0.0034; HR 2.15; 95% CI: 1.29-3.60).
Trial ID:
